

# **Test Definition: GBACC**

Gamma-Amino Butyric Acid Type A (GABA-A) Receptor Antibody by Cell Binding Assay, Spinal Fluid

### **Overview**

#### **Useful For**

Evaluating patients with suspected autoimmune encephalitis and autoimmune epilepsy

#### **Method Name**

Cell Binding Assay (CBA)

### **NY State Available**

Yes

## **Specimen**

### **Specimen Type**

**CSF** 

## **Specimen Required**

**Container/Tube:** Sterile vial **Specimen Volume:** 1 mL

#### **Forms**

<u>If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request</u> (T732) with the specimen.

## **Specimen Minimum Volume**

0.4 mL

### **Reject Due To**

Gross	Reject
hemolysis	
Gross lipemia	Reject
Gross icterus	Reject

## **Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
CSF	Refrigerated (preferred)	28 days	
	Frozen	28 days	



# **Test Definition: GBACC**

Gamma-Amino Butyric Acid Type A (GABA-A)
Receptor Antibody by Cell Binding Assay,
Spinal Fluid

Ambient	72 hours	

### Clinical & Interpretive

#### **Clinical Information**

Gamma-amino butyric acid type A (GABA-A) receptor autoantibodies are highly predictive of GABA-A receptor autoimmune encephalitis. Seropositive GABA-A receptor encephalitis patients have characteristic clinical-radiologic presentations including frequent seizures and multifocal lesions in the white matter. The majority of patients are treatable with immunotherapy.

### **Reference Values**

Negative

### Interpretation

Seropositivity for gamma-amino butyric acid type A receptor autoantibodies supports the clinical diagnosis of autoimmune encephalitis with neurological presentations including seizures and multifocal lesions in the white matter. A search for thymoma cancer, and a trial of immunotherapy should be considered.

#### **Cautions**

Negative results do not exclude the diagnosis of autoimmune encephalitis. Only 2% of cases of autoimmune encephalitis are associated with autoantibodies against gamma-amino butyric acid type A receptor.

#### Clinical Reference

- 1. O'Connor K, Waters P, Komorowski L, et al. GABAA receptor autoimmunity A multicenter experience. Neurol Neuroimmunol Neuroinflamm 2019;6(3):e552. doi:10.1212/NXI.000000000000552
- 2. Spatola M, Petit-Pedrol M, Simabukuro MM, et al. Investigations in GABAA receptor antibody-associated encephalitis. Neurology. 2017; 88(11): 1012–1020. doi:10.1212/WNL.000000000003713
- 3. Waters P, Irani S. GABA-A receptor antibodies and their clinical associations. Neurology 2017; 88:1010–1011
- 4. Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterization of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014;13(3):276–286

#### **Performance**

### **Method Description**

Patient specimen is applied to a composite slide containing transfected and nontransfected HEK-293 cells. After incubation and washing, fluorescein-conjugated goat-antihuman IgG is applied to detect the presence of patient IgG binding.(Package insert: IIFT: Neurology Mosaics, Instructions for the indirect immunofluorescence test. EUROIMMUN, FA\_112d-1\_A\_UK\_C13, 02/2019)



# **Test Definition: GBACC**

Gamma-Amino Butyric Acid Type A (GABA-A)
Receptor Antibody by Cell Binding Assay,
Spinal Fluid

### **PDF Report**

No

### Day(s) Performed

Monday through Sunday

### Report Available

5 to 10 days

## **Specimen Retention Time**

28 days

### **Performing Laboratory Location**

Rochester

### **Fees & Codes**

#### **Fees**

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

### **Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

### **CPT Code Information**

86255

#### **LOINC®** Information

Test ID	Test Order Name	Order LOINC® Value
GBACC	GABA-A-R Ab CBA, CSF	103715-9

Result ID	Test Result Name	Result LOINC® Value
620231	GABA-A-R Ab CBA, CSF	103715-9